Notice: Constant automattic\jetpack\extensions\social_previews\FEATURE_NAME already defined in /home2/theprkho/public_html/thepharmatimes.in/wp-content/plugins/jetpack/extensions/blocks/social-previews/social-previews.php on line 14
Aarti Industries Ltd. Q2FY15 Results - The Pharma Times | Pharma & Health Care News Portal

Aarti Industries Ltd. Q2FY15 Results


Mumbai, November 2014

— Q2FY15 Total Income at Rs. 761.16 crore, Y-o-Y growth 18 %

— Q2FY15 Net Profit at Rs. 50.72 crore, Y-o-Y growth of 20 %

— Board declares interim dividend of Rs. 2.25 per share

Editors’ Synopsis:

For the Quarter ended September 30, 2014:

  • Total Income increased by 17.9% to Rs. 761.16 crore in Q2FY15 from Rs. 645.35 crore of Q2FY14;
  • Net profit increased by 19.8% to Rs. 50.72 crore for Q2FY15 from Rs. 42.35 crore in Q2FY14;
  • EBIDTA increased by 15.05% to Rs. 121.98 crore for Q2FY15 from Rs. 106.02 crore in Q2FY14;
  • Q2FY15 EPS stood at Rs. 5.72 compared to Rs. 4.78 in Q2FY14 (Y-o-Y growth of 19.7 %)

For the Half Year ended September 30, 2014:

  • Total Income increased by 21.1% to Rs. 1500.93 crore in H1FY15 from Rs. 1238.99 crore of H1FY14;
  • Net profit increased by 42% to Rs. 92.15 crore for H1FY15 from Rs. 64.88 crore in H1FY14;
  • EBIDTA increased by 28.9 % to Rs. 234.95 crore for H1FY15 from Rs. 182.26 crore in H1FY14;
  • H1FY15 EPS stood at Rs. 10.40 compared to Rs. 7.32 in H1FY14 (Y-o-Y growth of 42.10 %)

Aarti Industries Limited (AIL), a leading company in the field of chemical industry, today declared its financial results for the second quarter and half year ended September 30, 2014.

Total income for the quarter ended September 30, 2014 stood at Rs. 761.16 crore compared to Rs. 645.35 crore in Q2FY14, an increase of 17.9%.

Comparing on quarterly basis, net profit of the company increased by 19.8% to Rs. 50.72 crore in Q2FY15 as against Rs. 42.35 crore registered during Q2FY14.

EBIDTA increased by 15.05% to Rs. 121.98 crore for Q2FY15 from Rs. 106.02 crore in Q2FY14.

EPS for Q2FY15 stood at Rs. 5.72 as compared to Rs. 4.78 in Q2FY14 thereby registering a growth of 19.7 %.

The Board of Directors declared interim dividend of 45%, Rs. 2.25 per share (on the face value of Rs 5 each).

For the half year ended September 30, 2014, the Company’s total income stood at Rs. 1,500.93 crore as compared to Rs. 1,238.99 crore in half year ended September, 2013, an increase of 21.1 %.

Net profit for H1FY15 stood at Rs. 92.15 crore which is an increase of 42% from Rs. 64.88 crore in H1FY14.

EBIDTA increased by 28.9 % to Rs. 234.95 crore for H1FY15 from Rs. 182.26 crore in H1FY14.

EPS for H1FY15 stood at Rs. 10.40 as compared to Rs. 7.32 in H1FY14 thereby registering a growth of 42.10 %.

Commenting on the financial performance of the company Mr. Rajendra Gogri, Chairman and Managing Director, Aarti Industries Ltd, said, “ We are delighted to announce good set of numbers for yet another quarter. We have seen good growth in our pharma segment—both at topline and at EBIT level.

With our various expansion projects getting commissioned in coming period, going forward, we are expecting volume growth in all the three segments in second half. This should boost our topline as well as bottomline line in coming period ,” he added.

The Pharma Times News Bureau

Recent Posts

Fortis Hospital, Bannerghatta Road Launches dedicated Parkinson’s Disease and Deep Brain Stimulation Clinic

-  This specialized division empowers patients with neurological disorders to reclaim their mobility through a…

6 days ago

Milestone set in Indian Medical History – SSI Mantra Surgical Robotic System Performs the First-Ever Successful Surgery on One-Year-Old Infant

SSI Mantra Robotic System performs a successful urology procedure on a one-year-old infant with a…

1 week ago

Manipal Hospital Ghaziabad organises Fire Safety Training to Enhance Emergency Response

Ghaziabad, April 22, 2024: In order to strengthen the safety and wellbeing of people, Manipal Hospital…

2 weeks ago

Professor Dr Robert Zeiser receives DKMS Mechtild Harf Science Award 2024

DKMS EMPHASIZES ITS COMMITMENT TO BLOOD CANCER RESEARCH, SUPPORTS YOUNG SCIENTISTS, AND RECOGNIZES OUTSTANDING RESEARCH…

3 weeks ago

Dr. Reddy’s launches drug-free migraine management device Nerivio® in Europe following successful launch in India

Dr. Reddy's has launched Nerivio® in Germany through its step-down subsidiary betapharm To be followed…

3 weeks ago

Ankura Hospital Doctors perform a successful Complex Lung Surgery on a 4-month-old Infant

 Hyderabad, April 13, 2024: Ankura Hospital for Women and Children is proud to announce a remarkable medical…

4 weeks ago